DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation

• US 9,155,705 B2
• Filed: 04/02/2009
• Issued: 10/13/2015
• Est. Priority Date: 04/03/2008
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Friedl, Thomas, Braun, Michael, Egusa, Kenji, Fujita, Hikaru, Maruyama, Megumi, Nishioka, Takaaki
• Primary Examiner(s): Arnold, Ernst V
• Assistant Examiner(s): Chang, Kyung Sook
• Application Number:
  US12/935,634
• Publication Number:
  US 20110206766A1
• Time in Patent Office: 2,385 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2059 Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/2095 Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
• CPC Class Codes: A61K 9/28 Dragees; Coated pills or tablets , e.g. with film or compression coating A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209
• CPC Class Codes: A61K 9/2813 Inorganic compounds
• CPC Class Codes: A61K 9/282 Organic compounds, e.g. fats
• CPC Class Codes: A61K 9/2866 : Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 : for osteoporosis
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/04 : Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Claims

1. A solid pharmaceutical composition comprising or made from:

(a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage range from about 0.5 mg to about 10 mg,

(b) metformin hydrochloride,

(c) a pharmaceutical excipient, and

(d) about 1 mg to 50 mg of L-arginine.

2. The pharmaceutical composition according to claim 1, wherein the 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is present in a dosage strength of 0.5, 1, 2.5, 5, or 10 mg.

3. The pharmaceutical composition according to claim 1, wherein the 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is present in a dosage strength of 2.5 mg.

4. The pharmaceutical composition according to claim 1, wherein metformin hydrochloride is present in a dosage range from about 100 mg to about 1500 mg.

5. The pharmaceutical composition according to claim 1, wherein metformin hydrochloride is present in a dosage strength of 250, 500, 625, 750, 850, or 1000 mg.

6. The pharmaceutical composition according to claim 1, wherein metformin hydrochloride is present in a dosage strength of 500 mg, 850 mg, or 1000 mg.

7. The pharmaceutical composition according to claim 1, wherein the 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine and L-arginine are present in a weight ratio from about 1:

20 to about 10;

1.

8. The pharmaceutical composition according to claim 1, wherein the excipient is selected from the group consisting of one or more fillers;

a binder;

a lubricant; and

a glidant.

9. The pharmaceutical composition according to claim 1, comprising copovidone as binder.

10. The pharmaceutical composition according to claim 9, further comprising corn starch, magnesium stearate, or colloidal anhydrous silica.

11. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a tablet selected from a mono-layer tablet, a bi-layer tablet, a press-coated tablet, and a tablet which is film-coated for drug-loading.

12. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a tablet comprising a film-coat.

14. The pharmaceutical composition according to claim 1, wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine has a particle size distribution of X90<

200 μ

m.

15. A pharmaceutical composition according to claim 1 made by a process comprising incorporating the active ingredients and about 1 mg to 50 mg of L-arginine in a pharmaceutical excipient selected from D-mannitol, corn starch, pregelatinized starch, copovidone, magnesium stearate, and colloidal anhydrous silica.

16. The pharmaceutical composition according to claim 1, wherein the pharmaceutical excipient comprises a filler.

17. The pharmaceutical composition according to claim 1, wherein the pharmaceutical excipient comprises a filler and a binder.

18. The pharmaceutical composition according to claim 1, wherein the pharmaceutical excipient comprises a filler, a binder, and a lubricant.

19. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a tablet comprising or made from:

(a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage range from about 0.5 mg to about 10 mg,

(b) metformin hydrochloride,

(c) a pharmaceutical excipient, and

(d) about 1 mg to 50 mg of L-arginine.

20. The pharmaceutical composition according to claim 19, wherein the pharmaceutical excipient comprises a filler.

21. The pharmaceutical composition according to claim 19, wherein the pharmaceutical excipient comprises a filler and a binder.

22. The pharmaceutical composition according to claim 19, wherein the pharmaceutical excipient comprises a filler, a binder, and lubricant.

23. The pharmaceutical composition according to claim 19, wherein the pharmaceutical excipient comprises a filler, a binder, a lubricant, and a glidant.

24. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a tablet comprising or made from:

(a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage range from about 0.5 mg to about 10 mg,

(b) metformin hydrochloride,

(c) a pharmaceutical excipient comprising corn starch, copovidone, magnesium stearate, and colloidal anhydrous silica, and

(d) about 1 mg to 50 mg of L-arginine.

25. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a tablet comprising or made from:

(a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage of about 2.5 mg,

(b) about 0.5 mg to about 10 mg of metformin hydrochloride,

(c) a pharmaceutical excipient, and

(d) about 1 mg to about 25 mg of L-arginine.

13. A solid pharmaceutical composition comprising or made from 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage range from about 0.5 mg to about 10 mg, metformin hydrochloride, about 1 mg to 50 mg of L-arginine, a filler, a binder, a glidant, and a lubricant.